Clinical trials: Intravenous Administration
Healthy Volunteers
A First-in-Human Study of KINE-101 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study that evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous (IV) and subcutaneous…
- Trial name
- NCT07343323
- Testing
- KINE-101
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kine Sciences Co., Ltd.
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have…
- Trial name
- NCT00413894
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 105 sites in Germany
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Pouchitis
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
When some people have their large bowel removed, a surgeon can make a "pouch" from part of the small bowel to connect it to the back passage (anus). Pouchitis is when the pouch becomes inflamed (swollen) or infected.
- Trial name
- NCT06443502
- Testing
- Vedolizumab, Concomitant Antibiotic Therapy
- Where
- 14 sites in Belgium, Croatia and 6 more
- Volunteers
- 30 people
- Sponsor
- Takeda
Sickle Cell Disease
Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem…
- Trial name
- NCT06287086
- Testing
- BRL-101 autologous hematopoietic stem and progenitor cells injection
- Volunteers
- 1 people
- Sponsor
- Bioray Laboratories
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Postmenopausal Osteoporosis
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy…
- Trial name
- NCT02598453
- Testing
- Ibandronate
- Where
- 60 sites in United States
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Atrial Flutter
Cardiac Electrophysiological Study
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
- Trial name
- NCT00616629
- Testing
- AZD1305
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Lupus Nephritis
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus…
- Trial name
- NCT00705367
- Testing
- Abatacept
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Beta-Thalassemia
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in subjects with Transfusion-Dependent β-Thalassemia (TDT).
- Trial name
- NCT05577312
- Testing
- BRL-101
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Bioray Laboratories
SMA - Spinal Muscular Atrophy, Gene Therapy
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
- Trial name
- STR1VE (NCT03306277)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Novartis Gene Therapies
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Bronchiectasis, Lower Respiratory Infection
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.
- Trial name
- NCT02096315
- Testing
- POL7080
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Polyphor Ltd.
Community-acquired Infection
An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the…
- Trial name
- NCT01267968
- Testing
- GSK2251052
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
This is a study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg of Prolastin-C (alpha1-proteinase inhibitor [alpha1-PI] [Human]), compared to weekly infusions of 60 mg/kg of Prolastin-C in patients with…
- Trial name
- SPARK (NCT01213043)
- Testing
- Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Grifols Therapeutics LLC
Advanced Malignancies, Solid Tumors
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
- Trial name
- NCT00426140
- Testing
- Patupilone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
The sponsor wants to investigate in this study how well the test medicine is taken up by the body when given orally (by mouth) as a tablet and solution, and as a solution for infusion (into a vein).
- Trial name
- NCT04136327
- Testing
- GLPG1972 film-coated tablets, [14C]-GLPG1972 solution for infusion, [14C]-GLPG1972 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Arthritis, Rheumatoid
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
- Trial name
- NCT03241446
- Testing
- Tilmanocept
- Sponsor
- Navidea Biopharmaceuticals
Pharmacokinetics in Healthy Adults
Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration
The proposed study aims to assess the time above MIC (4 mg/mL), and the pharmacokinetics/pharmacodynamics and bioavailability of 1 g ceftriaxone administered by constant rate subcutaneous infusion over 2 hours compared with 1 g…
- Trial name
- NCT02561442
- Testing
- ceftriaxone
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- scPharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.